Changes in the abundance of Actinobacteriota and Escherichia Shigella in HCC patients treated with the triple therapy of local therapy combined with lenvatinib and PD-1 inhibitors may be related to the triple therapy effect. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.